Blog
56 Articles

Targeting the Undruggable KRAS Protein
Dr. Shubham Pant is focusing his research on effective treatments for the KRAS mutation, found in 90% of pancreatic cancers.

Finding More Clues about Circulating Tumor DNA
Researcher Dr. Gehan Botrus looks at circulating tumor DNA for genetic information on a patient’s pancreatic cancer to personalize treatment.

Studying a New Approach for the Liquid Biopsy
Drs. Allyson Ocean and Ying-Hsiu Su lead a liquid biopsy pilot study looking for KRAS proteins in urine, to detect pancreatic cancer.

A Look at MEK and Autophagy Inhibition
Dr. Conan Kinsey looks at the MEK pathway as way to make immunotherapy more effective for pancreatic cancer patients.

An Interview with Dr. Tyler Jacks
Dr. Tyler Jacks is one of the leading pancreatic cancer researchers. Read what he has to say about KRAS, organoids, and running a lab in a pandemic.

High-Dose Vitamin C Targeting KRAS and BRAF in Pancreatic Cancer
Learn how Dr. Manish Shah is leading clinical trials using high-dose Vitamin C to target KRAS and BRAF mutations in pancreatic cancer.

Targeting Mutant KRAS with Immunotherapy
Dr. Beatriz Carreno explains how her team is targeting the KRAS mutation with a pancreatic cancer vaccine to make the immune system work against cancer.

Challenge Grant Recipients Moving Forward
The Pancreatic Cancer Collective awarded four teams a second round of New Therapies Challenge Grants, to further develop new pancreatic cancer treatment.

Studying One Family’s Mutations May Change Pancreatic Cancer Treatment and Prevention
Dr. Sahar Nissim is studying the genetic mutations in one family predisposed to pancreatic cancer, to find new ways to combat the disease.

Dousing Out-of-Control KRAS Signaling in Pancreatic Cancer
Rene Bernards and his team are targeting the signaling pathway of the KRAS mutation, which occurs in almost all pancreatic cancers.

Immunotherapy to Attack a Common Pancreatic Cancer Mutation
Researchers are testing a type of immunotherapy to attack a variant of the KRAS mutation; KRAS mutations occur in almost all pancreatic cancers.